TREAT Steward

TREAT

Antimicrobial Stewardship software with personalized decision support

SUNDHEDS

Who am I?



Mads Lause Mogensen M.Sc., Ph.D. Chief Executive Officer (CEO)

Aalborg, Denmark





We are part of the Judex family







The Challenge of the "Super bugs"


- the microbiological battle toughens

- Antimicrobial resistance is one of the world's most pressing public health threats
 - Two sided problem that in 2050 it will kill more people than cancer
- Excessive or inappropriate prescription of antimicrobials contributes to the problem – Today 30-50% of all antibiotic prescriptions are useless
- Antimicrobial treatment is given empirically before microbiology results are available - During the first days of hospitalization prescription is an "educated guess"










- binds everything together in one Antimicrobial Stewardship software tool


	Worklist			Sepsis	Patient	Site of in	fection		ummary and		Review previous	Myr	atients	
			pr	esentation	background		licetion		treatment		encounter	1019 P		
	Patient ID	Activate patient												
The core of the Sy:	Search in list	Awaiting ID approval										TEMS	ן כ	
Causal Probabilist	Search III list	Q Search Department All V Restricted antibiotics Change medication Dispense												
Calibrated to e	Patient Id	Name	D	Department	Prescribed	antibiotics	DT	Se	elected in Treat		Patient status	Pharmacy	PDF	ור
	3456-1245	Peter Peterson	0	Acute ward							Activate Treat			ħ
Quality assurance and	5/-1245	Anders Anderson	1	Medcine E				Ce	efuroxime IV?	Aw	aiting ID approval		A	U
specialist and A-team review tool	1245-7د	James Jameson	5	Medcine F				C	Cefuroxime IV	Cha	ange medication		A	
Teview tool	345678-1245	Jens Jensen	2	Acute ward	Cefuro	Cefuroxime IV		C	Cefuroxime IV		\oslash	Dispensed* (03/04-2014)	A	
	456789-1245	Tom Tomsen	10	Acute ward	Levofloxacin IV		0	C	Cefuroxime IV (ange medication		A	
	567890-1245	Peter Peterson	8	Medicine B	Meropenem IV		3	Va	Vancomycin IV C		ange medication		A	
	678901-1245	Christian Christenson	2	Acute ward	Vancomycin IV		0	Va	Vancomycin IV		\oslash	Dispense	A	
	345901-1245	Hugo Smith	5	Medicine C	Piperacillin-tazobact IV		2	Pipera	Piperacillin-tazobact IV		ate culture results		A	
	789012-1245	Peter Hansen	4	Acute ward	Cefuroxime PO		4	C	Cefuroxime PO		\oslash	Expired	A	
	890123-1245	Leon Leonson	0	Acute ward							Activate Treat			
	990123-1245	Jan Janson	0	Acute ward				PenicillinG IV			Activate Treat	Dispense		
	901234-1245	Henrik Henrikson	1	Acute ward	Ampicilin PO		0				\odot	Dispense	A	
	012345-1245	Bill Billson	2	Medicine B	Meropenem IV		0	М	Meropenem IV?		aiting ID approval		A	ΗI
	Show more pat		00	1045)							C	Activate selected	patient	
		omsen (4567	89	-1245)—										ור
	Antimicrobia	ntimicrobial treatments Previous TREAT encounters											1	
	Treatment		op dat		/day Date		_	pisode			Comment	Physisian	PDF	
	PenicillinG I	/ 07-04-2014 14-	04-20	14 1 MU	3 11-05-2014		_	2			omment in text here		A	
	11				11-05-2014			1	2 Doctor's comment in text here					
						11-05-2014	· .	1	1	Doctor's co	omment in text here	. Doctor2	A	

 Doctor's comment in text here...
 Doctor1

 Doctor's comment in text here...
 Doctor2




456789-1245 Tom Tomsen (55y, male) 🔒 🗘 🛓	Textual Guideline
Worklist Sepsis Patient Site of infection Summary and reatment Review previous My patients	
Demography Admission: 09/22/2014 08:46 Episode onset: 09/22/2014 08:46 Department: Acute ward	
Background Place of acquisition Community Lung disease COPD	
Vital parameters Temperature 38.9° C Heart rate 87 bpm Respiratory rate 22 /min SaO2 oximetry 87 %	
Local findings Cough Productive Dysuria Yes Eukocyturia Yes Flank pain Yes	
Lab values WBC 15.6 K/ul Neutrophils 8.2 K/ul Hematocrit 40 % Platelets 170 K/ul	QUALITY ASSURANCE
Sodium 139 mEq/l Glucose 130 mg/dl Urea 43 mg/dl Creatinine 1.33 mg/dl Albumin 4.0 g/dl AST 26 U/l Total bilirubin 0.88 mg/dl Aklaline phospha 99 mEq/l	TREAT helps you answer the following questions:
Albumin 4.0 g/dl AST 26 U/l Total bilirubin 0.88 mg/dl Alkaline phospha 99 mEq/l pH 7.31 PvO2 33.9 mmHg PvCO2 69.5 mmHg HCO3 34.0 mEq/l Lactate 28 mg/dl	 Is the patient infected and how severe is it? At which focus site is the patient infected?
Microbiology Date Sample type Location Pathogen Quantity/Result ESBL Amika Ampi AmpCI Cftza Cftria Cefur Cipro Colis Erta	 What is the most likely bug to treat? What is the coverage of the different antimicrobials at my
14/05/2014 Culture Urine E. Coli 10^4/ml + S R S R R R R S S 14/05/2014 Culture Blood No growth 0/3 bottles - <t< td=""><td>hospital? • How should I balance the benefit of treating the patients</td></t<>	hospital? • How should I balance the benefit of treating the patients
Sepsis meter	with the direct cost, side effects and ecological costs?
Suggested diagnosis In-vivo coverage: Pip-tazo IV [95%] Recommended treatments Urosepsis 88% Pneumonia 9% Asymp. Bacteriuria 5% Pseudomonas sp (UTI) 6% Pino - Toto - Toto 96% Production of the second o	STATISTICS AND SURVEILLANCE
Pyelonophritis 1% Proteus sp (UTI) 4% Ciprofloxacin PO 206 Acute bronchitis 1% Citrobacter (UTI) 2% Covered Not covered Ciprofloxacin IV 134	Mangement Report
Select diagnosis and treatment Antibiotic treatment Iteratment Treatment Please specify your treatment and the reason for your choice Piperacillin-tazobact IV Y mg a day Ward greater caponing Please write a comment Approve	
	My Patients SYSTEMS




Clinical Results on Treatment Quality

- improves empirical coverage and reduces consumption of broad-spectrum antimicrobials


• Amazing findings based on research from 8000+ patients in e.g. Denmark, Israel, Italy and Germany





Economic Benefits

- TREAT Steward provides an excellent business case







Linked in



WHO and ECDC say that antibiotic resistance is one of the most pressing public health threats ... it will surpass cancer in 2050



An excellent solution that combines every aspect of antimicrobial treatment and stewardship ... we have shown we can deliver



TREAT Steward has been validated successfully in clinical practice ... it can save lives, money and reduce antibiotic consumption



If you are interested or have additional questions please pass by CSC's booth.

